Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

The challenge of antimicrobial resistance is becoming increasingly critical worldwide, prompting the need for advanced diagnostic tools to effectively detect and manage resistant infections. The antimicrobial resistance diagnostics market is evolving rapidly, driven by technological innovations and rising awareness about the importance of early detection. This overview explores the current market size, growth drivers, segmentation, emerging trends, competitive players, and regional highlights shaping the future of this vital healthcare sector.

Antimicrobial Resistance Diagnostics Market Size and Projected Growth

The antimicrobial resistance diagnostics market has witnessed substantial expansion in recent years. It is expected to grow from $4.41 billion in 2025 to $4.74 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.5%. This historical growth has been fueled by the increasing incidence of antibiotic-resistant infections, a strong dependence on traditional culture-based diagnostics, a rise in hospital-acquired infections, heightened awareness of antimicrobial stewardship, and the expansion of clinical microbiology laboratories worldwide. Looking ahead, the market is anticipated to reach $6.23 billion by 2030, with a CAGR of 7.1%. Factors supporting this future growth include advancements in PCR and NGS diagnostic technologies, greater government funding for antimicrobial resistance (AMR) surveillance programs, a rising shift toward rapid diagnostic tests, expansion in pharmaceutical and biotechnology research, and the integration of data-driven decision support tools. Key market trends during the forecast period are the growing use of rapid and point-of-care AMR diagnostics, increasing demand for targeted and personalized antimicrobial therapies, enhanced surveillance of drug-resistant pathogens, expanded molecular and genomic diagnostic testing, and stronger hospital infection control and stewardship initiatives.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25696&type=smp

Key Factors Fueling Growth in the Antimicrobial Resistance Diagnostics Market

One of the primary drivers of this market is the rising prevalence of drug-resistant infections, which occur when microbes such as bacteria, viruses, fungi, or parasites develop the ability to withstand treatments that were once effective. This resistance complicates standard treatments and makes infections more difficult to control. A significant contributor to this problem is the overuse of antibiotics in agriculture, where low doses are regularly added to animal feed, promoting resistance that can transfer to humans through the food supply. Antimicrobial resistance diagnostics—including rapid genetic testing and culture-based sensitivity assays—are critical in addressing this challenge by enabling early detection of resistant pathogens, guiding precise therapies, and reducing unnecessary use of broad-spectrum antibiotics.

For instance, data released in November 2024 by the UK Health Security Agency (UKHSA) revealed that serious antibiotic-resistant infections in England increased from 58,224 cases in 2022 to about 66,730 in 2023, alongside a 2.4% rise in antibiotic use during the same period. This rising prevalence of resistant infections underscores the urgent need for improved diagnostic solutions, thereby driving growth in the antimicrobial resistance diagnostics market.

https://www.thebusinessresearchcompany.com/report/antimicrobial-resistance-diagnostics-global-market-report

Antimicrobial Resistance Diagnostics Market Global Footprint: Which Region Holds Market Leadership?

Detailed Segmentation of the Antimicrobial Resistance Diagnostics Market

The report categorizes the antimicrobial resistance diagnostics market into multiple key segments to provide a thorough analysis:

1) Product Type: Kits and Reagents; Instruments and Consumables

2) Pathogen: Drug-Resistant Streptococcus Pneumoniae (DRSP), Drug Resistant Campylobacter (DRC), Clostridium Difficile (CD), Methicillin Resistant Staphylococcus Aureus (MRSA), Drug Resistant Neisseria Gonorrhoeae (DRNG), Drug Resistant Salmonella (DRntS), and other pathogens

3) Technology: Microbiology Culture, Immunoassay, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Mass Spectrometry, Rapid and Point of Care, among others

4) End-User: Hospitals and Clinics, Diagnostics Laboratories, Research Institutes, Pharmaceutical and Biotechnology Companies, and other users

Further sub-segments include specific product types such as DNA and RNA extraction kits, PCR reagents, immunoassay reagents, stains and dyes, culture media, PCR machines, UV-Vis spectrophotometers, NGS systems, microarray scanners, automated liquid handlers, and sample collection tubes and swabs.

Cutting-Edge Innovations Transforming the Antimicrobial Resistance Diagnostics Industry

Leading companies in the antimicrobial resistance diagnostics sector are increasingly focusing on innovative technologies to improve the speed, accuracy, and clinical utility of testing. A significant advancement is the adoption of point-of-care antimicrobial susceptibility testing (AST) systems, which enable near-patient tests to rapidly identify effective antibiotics for infections. This helps clinicians make quicker, more targeted treatment decisions and supports antimicrobial stewardship by reducing unnecessary antibiotic prescriptions.

A notable example is the June 2023 launch of the PA-100 AST System by Sysmex Corporation, a Japan-based diagnostic solutions provider. This point-of-care platform analyzes urine samples, detecting bacterial presence and antibiotic susceptibility in about 30 minutes. The system uses microfluidic single-cell analysis, allows near-patient testing, and automates reporting, thereby facilitating timely and precise clinical decision-making to combat antimicrobial resistance.

Key Market Players Leading the Antimicrobial Resistance Diagnostics Sector

Several prominent companies are shaping the antimicrobial resistance diagnostics market, including:

F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, bioMerieux SA, Sysmex Corporation, Bio Rad Laboratories Inc, QIAGEN NV, Seegene Inc, Alifax S r l, Accelerate Diagnostics Inc, Molsid SAS, Genetic Signatures Limited, iFAST Diagnostics Ltd, Astek Diagnostics Inc, OpGen Inc, T2 Biosystems, Jiangsu Medomics Medical Technology Co Ltd, Cepheid, Luminex Corporation, Bruker Corporation, and Hologic Inc.

Geographical Trends and Market Leadership in the Antimicrobial Resistance Diagnostics Sector

In 2025, North America dominated the antimicrobial resistance diagnostics market, holding the largest regional share. Meanwhile, the Asia-Pacific region is expected to experience the fastest growth during the forecast period. The market report covers multiple regions, including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, providing a comprehensive view of global market dynamics.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model